JD Supra

FDA Approves Colony Stimulating Factor-1 Receptor (Csf-1R) Blocking Antibody for Treatment of Chronic Graft-Versus-Host Disease (Cgvhd)

Jason Jardine, Makoto Tsunozaki Ph.D. On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO ...
wvgazettemail.com

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for ...
Pharmabiz

US FDA accepts Abbisko Therapeutics’ NDA for pimicotinib to treat tenosynovial giant cell tumour

US FDA accepts Abbisko Therapeutics’ NDA for pimicotinib to treat tenosynovial giant cell tumour: Shanghai Thursday, January 15, 2026, 14:30 Hrs [IST] Abbisko Therapeutics Co Lt ...
ascopubs.org

Investigation of colony stimulating factor-1 receptor (CSF-1R) expression in peripheral monocytes of breast cancer patients for tumor associated macrophages (TAM): A pilot study

The yield of peripheral blood stem cells (PBSC) in hematological or solid tumour patients treated with high dose chemotherapy and hemopoietic growth factors No significant financial relationships to ...
PharmiWeb

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

Peer-reviewed publication in “The Oncologist” is now available onlineInvestigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day ...